Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rani Therapeutics Holdings Inc Cl A (RANI)

Rani Therapeutics Holdings Inc Cl A (RANI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,774
  • Shares Outstanding, K 121,512
  • Annual Sales, $ 1,030 K
  • Annual Income, $ -30,020 K
  • EBIT $ -47 M
  • EBITDA $ -47 M
  • 60-Month Beta 0.40
  • Price/Sales 191.49
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 323.67% (-34.51%)
  • Historical Volatility 173.17%
  • IV Percentile 56%
  • IV Rank 23.84%
  • IV High 1,124.40% on 05/22/25
  • IV Low 73.08% on 09/09/25
  • Expected Move (DTE 7) 0.2210 (13.90%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 474
  • Volume Avg (30-Day) 2,784
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 157,801
  • Open Int (30-Day) 168,146
  • Expected Range 1.3690 to 1.8110

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.05
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +88.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +15.22%
on 12/03/25
2.6300 -39.54%
on 11/06/25
-0.9100 (-36.40%)
since 11/05/25
3-Month
0.4453 +257.06%
on 10/13/25
3.8700 -58.91%
on 10/22/25
+1.0878 (+216.61%)
since 09/05/25
52-Week
0.3870 +310.85%
on 07/15/25
3.8700 -58.91%
on 10/22/25
-0.2600 (-14.05%)
since 12/05/24

Most Recent Stories

More News
Rani Therapeutics to Participate in the Evercore Healthcare Conference

SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 1.5900 (+1.27%)
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara...

RANI : 1.5900 (+1.27%)
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 1.5900 (+1.27%)
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

RANI : 1.5900 (+1.27%)
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran ...

RANI : 1.5900 (+1.27%)
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties...

RANI : 1.5900 (+1.27%)
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor...

RANI : 1.5900 (+1.27%)
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.

RANI : 1.5900 (+1.27%)
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.

RANI : 1.5900 (+1.27%)
Rani Therapeutics Announces Research Agreement with Chugai

RANI : 1.5900 (+1.27%)

Business Summary

Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif.

See More

Key Turning Points

3rd Resistance Point 1.7750
2nd Resistance Point 1.7200
1st Resistance Point 1.6550
Last Price 1.5900
1st Support Level 1.5350
2nd Support Level 1.4800
3rd Support Level 1.4150

See More

52-Week High 3.8700
Fibonacci 61.8% 2.5395
Fibonacci 50% 2.1285
Fibonacci 38.2% 1.7175
Last Price 1.5900
52-Week Low 0.3870

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar